⁃ All patients must meet the following inclusion criteria during the identification period:

• Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.

• ≥ 18 years old at the time of enrollment

• Written informed consent must be obtained prior to any data collection

• Willing to participate in Quality of Life post treatment date collection for 1 year